Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

CAMBRIDGE, Mass., March 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2007. At December 31, 2007, Idenix's cash, cash equivalents and marketable securities totaled $112.0 million.
Significant company events for 2007 included:

-- The approval and launch of Sebivo(R) in major markets on a worldwide

basis, including China and the European Union. By year-end 2007,

Tyzeka(R)/Sebivo(R) (telbivudine) was approved in more than 50

countries.

-- The discontinuation of development of valopicitabine, or NM283, which

had been Idenix's lead drug candidate for the treatment of hepatitis C.

-- A strategic restructuring whereby Novartis Pharma AG assumed full

responsibility for the development, manufacturing and commercialization

activities relating to Tyzeka/Sebivo effective October 1, 2007 in

exchange for a royalty on worldwide product sales. As a result of these

changes, Idenix reduced its workforce by approximately 100 positions,

the majority of which supported the development and commercialization

of Tyzeka/Sebivo in the United States and Europe.

-- The expansion of Idenix's pipeline to include a novel non-nucleoside

reverse transcriptase inhibitor for the treatment of HIV-1 that is

currently in clinical development, and several novel direct-acting HCV

product candidates, including next-generation nucleoside/nucleotide

polymerase inh
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
2. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Notice of Bradmer Pharmaceuticals Conference Call
6. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
7. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
8. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
9. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
10. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
11. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a new ... and co-founder of the Ace Medical Weight Loss Center in ... broad look at the industry of weight loss, and how ... film and in television shows, however, she says the topic ... and played for basic laughs, which she believes impacts whether ...
(Date:12/17/2014)... 17, 2014 This prestigious award ... that have made outstanding and innovative contributions to ... progression of private practice physical therapy by the ... Association. , On behalf of Performance Physical Therapy, ... CEO of Performance accepted the award at the ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 A group of ... for Longevity, today, in reaction to a recent statement by ... of brain training and derogated the efficacy of all brain ... agreed with the parts of the center’s statement critical of ... the center had also overstated its case, in a document ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... which was just approved for treating leukemia, also shows promise ... Drug Administration approved the use of a promising anti-leukemia drug ... The drug, Gleevec, administered as a pill once a day, ... its ability to target and kill cancer cells without attacking ...
... study on a vaccine made from the immune system ... a promising. Dr. Johannes Vieweg, associate professor of urology ... Medical Center in Durham, tested the vaccine on 13 ... uses the men's own dendritic cells, extracted white blood ...
... native to the South Sea Islands. It is a herb ... diseases. The herb is commonly used by consumers as a ... spasms. According to experts, the herb behaves like a class ... ,Benzodiazepines have been shown to be habit-forming when taken ...
... a person's face could unveil whether he or she is ... non smokers.A study by dermatologists, published in The Lancet, shows ... that breaks down collagen in the skin.// ,Collagen is ... elasticity of the skin. When this starts to deteriorate, skin ...
... Doctors investigating a theory that contemporary orgasms succor fertility found ... from their partners than those that did not. The best ... with your partner, scientists have ascertained. ,Dr Cathy, from ... with an average age of 32. //The women were asked ...
... best foot forward in completing its social responsibility. ... Zyban, its anti-smoking drug. Glaxo is aiding companies ... policy, along with providing teams to help in ... corporate, which have negotiated for this 'no-smoking' environment, ...
Cached Medicine News:
(Date:12/15/2014)... , December 15, 2014 Investor-Edge has ... ZGNX ), Eli Lilly and Company (NYSE: ... (NYSE: SNY ), and Novartis AG (NYSE: ... be accessed at: http://investor-edge.com/register . On Friday, ... 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish ...
(Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... InterMune, Inc. (Nasdaq: ITMN ) today ... development program for pirfenidone and idiopathic pulmonary fibrosis (IPF) ... European Respiratory Society (ERS), to be held September 18-22 ... Executive Officer and President of InterMune, said, "We are ...
... Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin ... announced today that its President and Chief Executive Officer ... highlighting recent developments at the Rodman & Renshaw 12th ... will take place on Wednesday, September 15, 2010 at ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 2Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: